Carfilzomib reverses pulmonary arterial hypertension

Cardiovascular Research

Volumn 110, Issue 2, 2016, Pages 188-199

  Wang, Xinhong ^a,b   Ibrahim, Yasmine F ^a,c   Das, Dividutta ^a   Zungu Edmondson, Makhosazane ^a   Shults, Nataliia V ^a   Suzuki, Yuichiro J ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

^c MINIA UNIVERSITY   (Egypt)

Author keywords

Apoptosis; Carfilzomib; Proteasome inhibitor; Pulmonary heart disease; Pulmonary hypertension

Indexed keywords

BORTEZOMIB; CARFILZOMIB; HEAT SHOCK PROTEIN 90; LUNG RESISTANCE PROTEIN; NITROPRUSSIDE SODIUM; OVALBUMIN; PIFITHRIN ALPHA; RAZOXANE; SEMAXANIB; SMALL INTERFERING RNA; UBIQUITIN; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; DRUG EFFICACY; DRUG MECHANISM; HEART RIGHT VENTRICLE PRESSURE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOXIA; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY MUSCLE; PULMONARY HYPERTENSION; RAT; TREATMENT DURATION; UBIQUITINATION; ANIMAL; CELL CYCLE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; MALE; OLIGOPEPTIDES; PROTEASOME INHIBITORS; PULMONARY ARTERY; RATS, SPRAGUE-DAWLEY;

EID: 84966521130     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw047     Document Type: Article

References (35)

1. Archer SL, Michelakis ED. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol 2006;21:385-392.
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43: 13S-24S.
3. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:261-272.
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW,Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
5. Benza RL, Miller DP, Frost A, Barst RJ, Krichman AM, McGoon MD. Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry. Transplantation 2010;90:298-305.
6. Humbert M, Sitbon O, Yäci A, Montani D, O'Callaghan DS, Jäs X, Parent F, Savale L, Natali D, Günther S, Chaouat A, Chabot F, Cordier JF, Habib G, Gressin V, Jing ZC, Souza R, Simonneau G, French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-555.
7. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079-1087.
8. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 2007;4:319-329.
9. Suzuki YJ, Nagase H, Wong CM, Kumar SV, Jain V, Park AM, Day RM. Regulation of Bcl-xL expression in lung vascular smooth muscle. Am J Respir Cell Mol Biol 2007;36: 678-687.
10. Ibrahim YF,Wong CM, Pavlickova L, Liu L, Trasar L, Bansal G, Suzuki YJ. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing. J Am Heart Assoc 2014;3:e000520.
11. Giuliano M, D'Anneo A, De Blasio A, Vento R, Tesoriere G. Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs. Ital J Biochem 2003;52: 112-121.
12. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-513.
13. Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, Habtemariam B, Bullock J, Bray JD, Hawes J, Palmby TR, Jee J, Adams W, Mahayni H, Brown J, Dorantes A, Sridhara R, Farrell AT, Pazdur R. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19:4559-4563.
14. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-6391.
15. Kortuem KM, Stewart AK. Carfilzomib. Blood 2013;121:893-897.
16. Li M, Dong X, Liu Y, Sun X, Li Z, He J. Inhibition of ubiquitin proteasome function suppresses proliferation of pulmonary artery smooth muscle cells. Naunyn Schmiedebergs Arch Pharmacol 2011;384:517-523.
17. Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, Ro JY, Oh YM, Lee SD, Lee YS. Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2012; 47:698-708.
18. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438.
19. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121:2747-2754.
20. Mizuno S, Farkas L, Al Husseini A, Farkas D, Gomez-Arroyo J, Kraskauskas D, Nicolls MR, Cool CD, Bogaard HJ, Voelkel NF. Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. Am J Respir Cell Mol Biol 2012;47: 679-687.
21. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
22. Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, Monte M, Carrier A, IoVanna JL, Dusetti NJ. TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell Death Differ 2012;19:1525-1535.
23. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, Knapton A, Chai J, Ferrans VJ. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin-and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001;48:297-304.
24. Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA. Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. PLoS One 2013;8:e70575.
25. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446:444-448.
26. Vincent DT, Ibrahim YF, Espey MG, Suzuki YJ. The role of antioxidants in the era of cardio-oncology. Cancer Chemother Pharmacol 2013;72:1157-1168.
27. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-1737.
28. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernández G, Rodŕguez A, Ló pez-Rivas A, Redondo JM. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002;277: 10883-10892.
29. Mishra R, Cool BL, Laderoute KR, Foretz M, Viollet B, Simonson MS. AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem 2008;283: 10461-10469.
30. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, Nakamaru K, Yano M, Kukidome D, Matsumoto K, Toyonaga T, Asano T, Nishikawa T, Araki E. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005;97:837-844.
31. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, Hirata Y. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004;110:444-451.
32. Ibe JC, Zhou Q, Chen T, Tang H, Yuan JX, Raj JU, Zhou G. Adenosine monophosphate-activated protein kinase is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol 2013;49:609-618.
33. Steiner E, Holzmann K, Elbling L, Micksche M, BergerW. Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets 2006;7:923-934.
34. Kowalski MP, Dubouix-Bourandy A, Bajmoczi M, Golan DE, Zaidi T, Coutinho-Sledge YS, Gygi MP, Gygi SP, Wiemer EA, Pier GB. Host resistance to lung infection mediated by major vault protein in epithelial cells. Science 2007;317:130-132.
35. Tanaka H, Kato K, Yamashita E, Sumizawa T, Zhou Y, Yao M, Iwasaki K, Yoshimura M, Tsukihara T. The structure of rat liver vault at 3.5 angstrom resolution. Science 2009; 323:384-388.